Source: Annual Congress 2009 - Severe asthma and its treatment
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Zielen, A. Lieb, J. De Monchy, S. De la Motte, F. Wagner, R. Fuhr, C. Munzu, S. Koehne-Voss, G. J. Riviere, J. S. Jaffe (Frankfurt, Munich, Berlin, Germany; Groningen, Netherlands; West Sussex, United Kingdom; Basel, Switzerland; East Hanover, United States Of America). Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels. Eur Respir J 2009; 34: Suppl. 53, 1869

Member's Comments

No comment yet.

Related content which might interest you: Omalizumab decreases IgE production in patients with severe allergic asthma Source: Annual Congress 2012 - Aspects of clinical asthma Year: 2012 Effect of humanized monoclonal anti-IgE antibody, omalizumab, on allergen challenge-induced nasal response in subjects with allergic rhinitis and allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001 Omalizumab inhibits allergen challenge-induced nasal response Source: Eur Respir J 2004; 23: 414-419 Year: 2004 The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Source: Eur Respir J 2001; 18: 254-261 Year: 2001 Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma Source: Annual Congress 2009 - Severe asthma and its treatment Year: 2009 Allergen activates eosinophils of atopic bronchial asthma patients via IgE-mediated mechanism. Source: Virtual Congress 2020 – New insight into the pathogenesis of chronic lung diseases: asthma, COPD and others Year: 2020 Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges Year: 2009 Zinc in serum and induced sputum of patients with allergic rhinitis and allergic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004 Sublingual monomeric allergoid immunotherapy improves airway inflammation, airway hyperresponsiveness and clinical symptoms in allergic rhinitis and asthma Source: Eur Respir J 2006; 28: Suppl. 50, 439s Year: 2006 IPL576,092 reduces allergen-induced late asthmatic responses, sputum eosinophilia and airway hyperresponsiveness in mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 104s Year: 2003 Omalizumab reduces bronchial mucosal IgE and improves lung function in non-atopic asthma Source: Eur Respir J 2016; 48: 1593-1601 Year: 2016 Iron in serum and induced sputum of patients with allergic rhinitis and allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 445s Year: 2006 Humoral markers of inflammation in induced sputum of patients with bronchial asthma and allergic rhinitis in relation to exposure to pollen allergens Source: Eur Respir J 2004; 24: Suppl. 48, 595s Year: 2004 Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma Source: Eur Respir J 2002; 20: 73-78 Year: 2002 Comparison of late allergic inflammatory responses in asthma and rhinitis after nasal and bronchial allergen challenge Source: Eur Respir J 2001; 18: Suppl. 33, 269s Year: 2001 A single nasal allergen challenge increases induced sputum inflammatory parameters in non-asthmatic patients with seasonal allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 163s Year: 2001 Lower airway inflammation and hyperresponsiveness in allergic and non-allergic rhinitis Source: Annual Congress 2011 - Asthma: risk factors and comorbidities Year: 2011 Immunotherapy prevents the development of asthma in subjects with allergic rhinitis Source: Eur Respir J 2001; 18: Suppl. 33, 482s Year: 2001 The role of mast cells in allergic, non-allergic and aspirin-induced asthma and rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 589s Year: 2005